Hey. So I'm in third year, and I'll be a student, and I have a-- I'm presently studying BSc. I'm studying a lesson, communicable diseases and epidemiology. We actually have to answer questions for exam in order, like for each disease, we have to write epidemiology, clinical features, treatment, prevention, complications. So can you like give me a pro forma that I can use for all the questions? Actually, not a pro forma, but, um... Uh, can you actually give me... You can give me the performer. Uh, I will send you the performer. I will give you the performer. Just, uh, give me any disease that I want according to that performer. Okay? Okay.
Polio
| Parameter | Details |
|---|---|
| Causative agent | Poliovirus - RNA virus, Family Picornaviridae, Genus Enterovirus |
| Types | 3 serotypes: Type 1 (most common, most paralytic), Type 2 (eradicated 2015), Type 3 (eradicated 2019) |
| Source of infection | Human case or carrier (no animal reservoir - anthroponosis) |
| Reservoir | Human only |
| Infective material | Faeces (primary), oropharyngeal secretions |
| Infectivity | Highly infectious; subclinical cases are the main source of spread |
| Pathogenicity | Low (~2% develop paralysis) |
| Antigenicity | Strong - immunity is type-specific and lifelong after infection or vaccination |
| Parameter | Details |
|---|---|
| Age group | Mainly children under 5 years ("Infantile Paralysis") |
| Sex | Males slightly more susceptible to paralytic form |
| Immunity | Type-specific; herd immunity threshold ~80-85% |
| Risk factors | Unvaccinated status, pregnancy, tonsillectomy (increases bulbar polio risk), strenuous exercise during prodrome, IM injections (provocation polio) |
| Parameter | Details |
|---|---|
| Mode | Faecal-oral (primary); droplet/respiratory (secondary) |
| Vehicle | Contaminated water, food, hands |
| Portal of entry | GI tract (oropharynx and intestine) |
| Incubation period | 4-35 days; usually 7-14 days for paralytic disease |
| Period of communicability | Virus shed in throat for ~1 week and in faeces for 3-6 weeks; most infectious in the week before and after symptom onset |
| Stage | Features |
|---|---|
| Incubation period | 7-14 days (range 4-35 days) |
| Prodromal / Minor illness stage | Fever, malaise, headache, sore throat, vomiting, abdominal pain (2-3 days) |
| Preparalytic stage | Return of fever (biphasic/dromedary fever), severe myalgia, meningism, muscle tenderness, spasm |
| Paralytic stage (Fastigium) | Flaccid paralysis - develops rapidly over 1-3 days; maximum within a few days |
| Convalescence | Recovery may occur for up to 6 months; paralysis after 6 months is permanent |
| Type | Features | Frequency |
|---|---|---|
| Inapparent / Subclinical | No symptoms | ~90-95% |
| Abortive poliomyelitis | Minor febrile illness, no CNS involvement, recovery in 2-3 days | ~4-8% |
| Non-paralytic (Aseptic meningitis) | Meningeal signs + fever, stiff neck/back; no paralysis; full recovery | ~1% |
| Paralytic poliomyelitis | Flaccid paralysis; sub-types below | <2% |
| Investigation | Details |
|---|---|
| Clinical diagnosis | Acute flaccid paralysis (AFP) in child <15 years with fever at onset |
| Routine labs | CBC (leukocytosis), CSF (increased cells - lymphocytes, normal glucose, slightly raised protein) |
| Specific tests | Stool culture for poliovirus (2 samples ≥24 hrs apart, within 14 days of onset) - gold standard; throat swab culture; CSF culture; RT-PCR |
| Gold standard | Stool virus isolation (culture) - poliovirus isolated and typed |
| Serology | 4-fold rise in neutralizing antibody titres |
| Definition | Criteria |
|---|---|
| Suspected case (AFP) | Any child <15 years with acute flaccid paralysis, OR any person of any age with paralytic illness if polio is suspected |
| Probable case | AFP + compatible epidemiological and clinical picture |
| Confirmed case | AFP + poliovirus isolated from stool specimen |
| Compatible case | AFP without adequate stool specimens and residual paralysis or death |
| Notifiable? | YES - notifiable under IDSP; any AFP case must be reported within 24 hours to CMO |
| Parameter | Details |
|---|---|
| Drug of choice | No specific antiviral treatment available |
| Supportive | IV immunoglobulin (in immunocompromised patients) |
| Respiratory support | Mechanical ventilation / iron lung for bulbar/respiratory involvement ⭐ |
| Rehabilitation | Physiotherapy, orthotic devices, corrective surgery in convalescence |
| Contraindicated | Glucocorticoids (steroids) worsen outcome; IM injections during febrile illness (provocation polio) |
| Type | Complication |
|---|---|
| Immediate / Acute | ⭐ Respiratory failure (bulbar polio - MOST DANGEROUS); acute myocarditis |
| Musculoskeletal | Flaccid paralysis, muscle wasting, joint deformities (equinus foot, claw foot), limb shortening |
| Neurological | Bulbar involvement - dysphagia, dysarthria, facial weakness |
| Long-term sequelae | ⭐ Post-Polio Syndrome (PPS) - new onset weakness, fatigue, pain 25-40 years after original illness |
| Psychological | Depression, social isolation due to disability |
| Complications of treatment | Pressure sores from immobility; respiratory infections |
⭐ Most dangerous complication: Respiratory failure in bulbar polio ⭐ Important long-term: Post-Polio Syndrome (PPS)
| Feature | OPV (Oral Polio Vaccine / Sabin) | IPV (Inactivated Polio Vaccine / Salk) |
|---|---|---|
| Type | Live attenuated | Killed / Inactivated |
| Route | Oral (2 drops) | Intramuscular injection |
| Immunity | Humoral + intestinal (mucosal IgA) | Humoral only (IgG) |
| Herd immunity | YES - virus shed, spreads immunity | No shedding |
| Risk | VAPP (Vaccine-Associated Paralytic Polio) ~1 in 2.7 million | None |
| Cold chain | Requires -20°C | Requires 2-8°C |
| Program | Details |
|---|---|
| Pulse Polio Programme (PPP) | Launched 1995-96 in India; OPV on National Immunization Days |
| National Polio Surveillance Project (NPSP) | AFP surveillance across India with WHO support |
| Global Polio Eradication Initiative (GPEI) | Launched 1988 by WHO, Rotary International, CDC, UNICEF |
| WHO target | Global eradication of wild poliovirus (WPV1 remains in Pakistan/Afghanistan) |
| India achievement | Polio-free certification by WHO - 27 March 2014 ⭐ |
| Surveillance | IDSP, IHIP, AFP surveillance network |
| Always Mention | Key Facts |
|---|---|
| Incubation period | 7-14 days |
| Period of communicability | Stool shedding 3-6 weeks |
| Notifiable disease | Yes - AFP reporting within 24 hours |
| Herd immunity threshold | ~80-85% |
| Drug of choice | None specific; supportive only |
| Gold standard diagnosis | Stool virus isolation (culture) |
| Most dangerous complication | Respiratory failure (bulbar polio) |
| India polio-free date | 27 March 2014 |
| National program | Pulse Polio Programme (1995-96) + GPEI (1988) |
| Hallmark sign | Asymmetric flaccid paralysis WITHOUT sensory loss |
Hi
Polio
| Section | Key Points |
|---|---|
| Agent | Poliovirus (RNA, Picornaviridae), 3 serotypes (Type 1 most paralytic) |
| Transmission | Faecal-oral; incubation 7-14 days |
| Reservoir | Human only (anthroponosis) |
| Clinical Types | Inapparent (90-95%), Abortive, Non-paralytic, Paralytic (<2%) |
| Hallmark sign | Asymmetric flaccid paralysis WITHOUT sensory loss |
| Most dangerous | Bulbar polio → respiratory failure ⭐ |
| Diagnosis (Gold std) | Stool virus isolation (culture) |
| Treatment | No specific antiviral; supportive only |
| Vaccines | OPV (live, oral) + IPV (killed, IM) |
| India polio-free | 27 March 2014 ⭐ |
| National Program | Pulse Polio Programme (1995-96); GPEI (1988) |
| Post-polio sequela | Post-Polio Syndrome (PPS) - 25-40 years later |
Hepatitis B
| Parameter | Details |
|---|---|
| Causative agent | Hepatitis B Virus (HBV) - DNA virus, Family Hepadnaviridae |
| Structure | Dane particle (42 nm) = complete virion; 22-nm spherical/tubular particles = excess HBsAg |
| Antigens | HBsAg (surface), HBcAg (core), HBeAg (e antigen - marker of active replication) |
| Genotypes | 10 genotypes (A-J); Genotype D common in India/Mediterranean; Genotype C associated with severe disease |
| Source of infection | Infected humans (acute cases, chronic carriers) |
| Reservoir | Human only (anthroponosis) |
| Infective material | Blood (primary), semen, vaginal secretions, saliva, breast milk, menstrual fluid. NOT faeces |
| Infectivity | Highly infectious - up to 10¹⁰ virions/mL in blood; virus survives drying for days |
| Pathogenicity | Most acute infections self-limiting; ~5-10% adults become chronic carriers; ~90% neonates become chronic |
| Parameter | Details |
|---|---|
| Age group | All ages; neonates and young children at highest risk of chronicity |
| Sex | Males more commonly develop chronic disease and hepatocellular carcinoma |
| Immunity | Anti-HBs antibody = protective; herd immunity threshold ~80-90% |
| High-risk groups | IV drug users, healthcare workers, dialysis patients, multiply transfused, organ transplant recipients, men who have sex with men, infants of HBsAg-positive mothers, sexual partners of carriers |
| Susceptibility | Immunosuppressed patients (dialysis, HIV, chemotherapy) respond poorly to vaccine |
| Parameter | Details |
|---|---|
| Mode | Parenteral (blood/blood products), Sexual (horizontal), Perinatal/Vertical (mother to child), Close contact |
| Routes | IV drug use (shared needles), unscreened blood transfusion, unsafe injections, sexual intercourse, mother-to-newborn at delivery |
| Portal of entry | Skin/mucous membranes (percutaneous or mucosal exposure) |
| NOT transmitted | Faecal-oral route - NOT documented |
| Incubation period | 45-180 days (mean 60-90 days) |
| Period of communicability | Several weeks before onset of symptoms; throughout HBsAg positivity; chronic carriers - lifelong |
| Stage | Features |
|---|---|
| Incubation period | 45-180 days (mean 60-90 days) |
| Prodromal stage | Anorexia, nausea, malaise, fever, arthralgia, rash (serum sickness-like reaction due to immune complexes) |
| Icteric stage (Fastigium) | Jaundice (in ~1/3 adults), dark urine, pale stools, hepatomegaly, tender liver, RUQ pain |
| Post-icteric / Convalescence | Gradual resolution; jaundice clears; liver enzymes normalize |
| Outcome | 90-95% adults - full recovery; 5-10% - chronic infection |
| Type | Features |
|---|---|
| Inapparent / Subclinical | Majority; no symptoms, seroconversion only |
| Acute symptomatic hepatitis B | Classic icteric illness; ~1/3 adults have jaundice |
| Fulminant hepatitis B ⭐ | Massive hepatic necrosis; hepatic encephalopathy; <1% but 60-80% mortality |
| Chronic hepatitis B | HBsAg persists >6 months; 5-10% adults, 90% neonates |
| Carrier state | HBsAg positive, no active liver disease |
| Investigation | Details |
|---|---|
| Routine labs | LFT: raised ALT/AST (ALT > AST), raised bilirubin; CBC; PT/INR (for severity); USG abdomen |
| HBsAg | First marker to appear; positive from 2-6 weeks before symptoms; persistence >6 months = chronic infection |
| Anti-HBc IgM | Marker of acute infection; present during "window period" ⭐ |
| HBeAg | Marker of active viral replication and high infectivity |
| HBV DNA (PCR) | Quantitative viral load; gold standard for assessing replication and treatment monitoring |
| Anti-HBs | Marker of recovery and immunity (also post-vaccination) |
| Phase | HBsAg | Anti-HBc IgM | Total Anti-HBc | Anti-HBs |
|---|---|---|---|---|
| Incubation | + | +/- | +/- | - |
| Acute hepatitis | + | + | + | - |
| Window period | - | + | + | - |
| Recovery | - | - | + | + |
| Vaccination | - | - | - | + |
| Chronic carrier | + | - | + | - |
| Definition | Criteria |
|---|---|
| Suspected case | Clinical jaundice + epidemiological risk factors |
| Probable case | Clinical hepatitis + raised transaminases |
| Confirmed case | HBsAg positive OR anti-HBc IgM positive in acute setting |
| Chronic case | HBsAg positive for >6 months |
| Notifiable? | YES - notifiable under IDSP; report to CMO |
| Parameter | Details |
|---|---|
| Acute Hep B | Usually no antiviral needed; spontaneous recovery in 95% |
| Severe acute Hep B | Antiviral indicated if coagulopathy, persistent symptoms >4 weeks, marked jaundice |
| Drug of choice (chronic) | Tenofovir Disoproxil Fumarate (TDF) 245 mg/day OR Tenofovir Alafenamide (TAF) 25 mg/day OR Entecavir 0.5 mg/day |
| Alternatives | Pegylated Interferon alfa-2a (finite duration, immune-mediated) |
| Second-line | Lamivudine (resistance common - avoid as first-line), Adefovir, Telbivudine |
| Special populations | Pregnancy: TDF preferred; Paediatrics: Entecavir or TDF; HIV co-infection: TDF + Emtricitabine (both cover HBV and HIV) |
| Fulminant hepatitis | Intensive care; consider liver transplantation |
| Type | Complication |
|---|---|
| Immediate / Acute | ⭐ Fulminant hepatic failure (most dangerous - <1% but high mortality) |
| Hepatic (chronic) | Chronic active hepatitis → Liver cirrhosis → Hepatocellular carcinoma (HCC) ⭐ |
| Extrahepatic | Polyarteritis nodosa (PAN), membranous glomerulonephritis, cryoglobulinaemia, aplastic anaemia |
| Neurological | Guillain-Barre syndrome (rare) |
| Coinfection | HDV (Hepatitis D) - only infects HBsAg-positive patients; causes more severe disease ⭐ |
| Long-term sequelae | HCC - HBV is the #1 cause of HCC worldwide; 25% of chronic carriers develop cirrhosis/HCC |
| Complications of treatment | Renal toxicity with TDF; lactic acidosis with nucleoside analogues; HBV flare on stopping antivirals |
⭐ Most dangerous acute complication: Fulminant hepatic failure ⭐ Most important long-term complication: Hepatocellular carcinoma (HCC)
| Feature | Details |
|---|---|
| Vaccine type | Recombinant DNA subunit vaccine (HBsAg produced in yeast) |
| Schedule (India UIP) | Birth dose (within 24 hrs) + 6, 10, 14 weeks (as Pentavalent vaccine) |
| Route | Intramuscular (deltoid in adults; anterolateral thigh in infants) |
| Efficacy | 90-95% in immunocompetent individuals |
| Seroprotection | Anti-HBs ≥10 mIU/mL = protected |
| Introduced in India UIP | 2002 (initially 10 states); universal by 2011 |
| Booster | Not recommended for immunocompetent persons after primary series |
| Program | Details |
|---|---|
| National Viral Hepatitis Control Programme (NVHCP) | Launched 28 July 2018 (World Hepatitis Day) by Ministry of Health, India ⭐ |
| Universal Immunization Programme (UIP) | Hep B vaccine as part of Pentavalent vaccine since 2002 |
| WHO target | Eliminate viral hepatitis as public health threat by 2030 (SDG 3.3); 90% reduction in new infections, 65% reduction in mortality |
| World Hepatitis Day | 28 July every year ⭐ |
| Surveillance | IDSP, IHIP, NVHCP portal |
| Always Mention | Key Facts |
|---|---|
| Incubation period | 45-180 days (mean 60-90 days) |
| Period of communicability | Throughout HBsAg positivity |
| Notifiable | Yes - under IDSP |
| Herd immunity threshold | ~80-90% |
| Drug of choice (chronic) | Tenofovir (TDF/TAF) or Entecavir |
| Gold standard diagnosis | HBsAg + HBV DNA (PCR) |
| Window period marker | Anti-HBc IgM ⭐ |
| Most dangerous complication | Fulminant hepatic failure (acute); HCC (long-term) |
| Not transmitted by | Faecal-oral route |
| National program | NVHCP (2018) |
| World Hepatitis Day | 28 July |
| Post-exposure prophylaxis | HBIG + Vaccine within 24 hours |
| Unique prodrome | Serum sickness-like (arthralgia + rash) |
Diarrhoeah
Note for exam: Diarrhoeal disease is a syndrome, not a single disease. In PSM exams, questions may ask about diarrhoea as a group or specifically about Cholera, Rotavirus, or Dysentery. This proforma covers the group - always specify causative agents where asked.
| Parameter | Details |
|---|---|
| Causative agents | Multiple - see below |
| Viruses (70-80% in children) | Rotavirus (#1 cause globally in <5 years), Norovirus, Astrovirus, Adenovirus |
| Bacteria (10-20%) | Vibrio cholerae, E. coli (ETEC, EPEC, EIEC, EHEC), Shigella spp., Salmonella spp., Campylobacter jejuni, Clostridium difficile, Staph. aureus |
| Protozoa (<10%) | Entamoeba histolytica, Giardia lamblia, Cryptosporidium |
| Source of infection | Infected humans, animals (zoonotic - Salmonella, Campylobacter), environment (V. cholerae in water) |
| Reservoir | Human (Shigella, Cholera), Animal (Salmonella, Campylobacter), Environment (Cholera - aquatic) |
| Infective material | Faeces, vomitus (Norovirus), contaminated food and water |
| Infective dose | Varies - Shigella/EHEC: as few as 10-100 organisms; V. cholerae: 10⁵-10⁸ organisms needed |
| Pathogenicity | High - especially in malnourished children; malnutrition and diarrhoea form a vicious cycle |
| Parameter | Details |
|---|---|
| Age group | All ages; highest morbidity and mortality in children <5 years |
| Sex | No significant difference |
| Immunity | Varies by pathogen; limited cross-protection between types |
| Risk factors | Malnutrition, bottle feeding (vs breastfeeding), lack of handwashing, immunocompromise (HIV), extremes of age |
| Protective factors | Breastfeeding (secretory IgA), Rotavirus vaccination, good nutritional status, vitamin A |
| Parameter | Details |
|---|---|
| Mode | Faecal-oral (primary route for ALL diarrhoeal pathogens) |
| Routes - 5 Fs | Fluids (water), Food, Fingers (hands), Flies, Fomites |
| Vehicle | Contaminated water (cholera, typhoid), food (Salmonella, Staph.), person-to-person contact (Shigella, Rotavirus) |
| Portal of entry | GI tract (oral ingestion) |
| Incubation period | Varies: Staph. aureus toxin: 1-6 hrs; Salmonella: 6-48 hrs; Shigella: 1-3 days; Rotavirus: 1-3 days; Cholera: few hours - 5 days; Giardia: 1-3 weeks |
| Period of communicability | Throughout symptomatic phase; asymptomatic carriers can shed for weeks (Salmonella typhi - up to 1 year) |
| Stage | Features |
|---|---|
| Incubation | Hours to weeks depending on pathogen |
| Prodromal | Nausea, anorexia, abdominal discomfort, borborygmi |
| Acute phase (Fastigium) | Loose/watery/bloody stools, abdominal cramps, fever (in invasive), vomiting, tenesmus (in dysentery) |
| Convalescence | Stool frequency and consistency normalize; fluid and electrolyte balance restored |
| Type | Mechanism | Example |
|---|---|---|
| Secretory | Enterotoxin → ↑cAMP/cGMP → ↑Cl⁻ secretion, ↓Na⁺ absorption | Cholera (V. cholerae), ETEC |
| Osmotic | Poorly absorbed solutes retain water in gut lumen | Viral gastroenteritis (Rotavirus), Giardia |
| Inflammatory / Dysenteric | Mucosal invasion → cytotoxin → inflammation | Shigella, EIEC, Entamoeba histolytica |
| Motility-related | Altered gut motility | IBS (non-infectious) |
| Type | Features | Common Agents |
|---|---|---|
| Watery diarrhoea | Large-volume, watery stools, NO blood; rapid dehydration | Cholera, Rotavirus, ETEC |
| Dysentery (bloody diarrhoea) | Small-volume, bloody mucoid stools, tenesmus, fever | Shigella, EIEC, Entamoeba histolytica, EHEC |
| Food poisoning | Short incubation, vomiting prominent, no fever | Staph. aureus, C. perfringens |
| Sign | No Dehydration | Some Dehydration | Severe Dehydration |
|---|---|---|---|
| General condition | Well, alert | Restless, irritable | Lethargic/unconscious |
| Eyes | Normal | Sunken | Very sunken |
| Thirst | Normal | Thirsty, drinks eagerly | Drinks poorly/cannot drink |
| Skin pinch | Goes back quickly | Goes back slowly | Goes back very slowly (>2 sec) |
| Action | Home ORS (Plan A) | ORS in facility (Plan B) | IV fluids (Plan C) |
| Investigation | Details |
|---|---|
| Clinical diagnosis | History of loose stools + dehydration; assess duration, frequency, blood/mucus, fever |
| Routine labs | Stool examination (macroscopic + microscopic - RBCs, pus cells, parasites, cysts); CBC; serum electrolytes; BUN/creatinine (for severity) |
| Stool culture | Gold standard for bacterial diarrhoea; identify pathogen and antibiotic sensitivity |
| Stool microscopy | Motile trophozoites of E. histolytica = amoebic dysentery; cysts = Giardia; RBCs in dysentery |
| Rapid tests | Cholera RDT (rapid dipstick); Rotavirus ELISA/antigen test |
| PCR | For viral identification (Norovirus, Rotavirus) |
| Hanging drop preparation | Darting motility of V. cholerae - confirms cholera |
| Definition | Criteria |
|---|---|
| Acute Diarrhoea | ≥3 loose/watery stools in 24 hours |
| Dysentery | Blood and/or mucus in stools |
| Cholera Suspected | Acute watery diarrhoea with/without vomiting, in patient ≥5 years, with severe dehydration |
| Cholera Confirmed | V. cholerae O1 or O139 isolated from stool culture |
| Notifiable? | YES - Cholera is notifiable under IDSP and under IHR 2005 (potential PHEIC); all clusters/outbreaks must be reported to CMO within 24 hours |
| Component | Amount per litre |
|---|---|
| Sodium chloride | 2.6 g |
| Trisodium citrate | 2.9 g |
| Potassium chloride | 1.5 g |
| Glucose (anhydrous) | 13.5 g |
| Total osmolarity | 245 mOsm/L |
| Plan | Dehydration | Setting | Amount |
|---|---|---|---|
| Plan A | None | Home | 50-100 mL ORS after each loose stool |
| Plan B | Some | Facility | 75 mL/kg over 4 hours |
| Plan C | Severe | Hospital IV | Ringer's Lactate 100 mL/kg (infants: over 3 hrs; children: over 1 hr) |
| Pathogen | Drug of Choice | Dose/Duration |
|---|---|---|
| Cholera | Doxycycline (adults) / Azithromycin (children/pregnant) | Doxycycline 300 mg single dose; Azithromycin 1g single dose |
| Shigella (Bacillary dysentery) | Ciprofloxacin (adults) / Azithromycin (children) | Cipro 500 mg BD x 3 days |
| Amoebic dysentery | Metronidazole + Diloxanide furoate | Metro 800 mg TDS x 5-10 days (luminal agent follows) |
| Giardia | Metronidazole or Tinidazole | Metro 400 mg TDS x 5 days |
| ETEC (Traveller's diarrhoea) | Usually self-limiting; Rifaximin if needed | Rifaximin 200 mg TDS x 3 days |
| C. difficile | Vancomycin (oral) or Fidaxomicin | Vancomycin 125 mg QDS x 10 days |
| Rotavirus/viral | Supportive only (ORS + Zinc) | No antivirals |
Antibiotics NOT routinely recommended for acute watery diarrhoea - reserve for cholera, dysentery, and specific confirmed bacterial causes
| Type | Complication |
|---|---|
| Immediate / Acute | ⭐ Severe dehydration → Hypovolaemic shock → Death (most dangerous, especially <5 years) |
| Metabolic | Hyponatraemia, Hypokalaemia, Metabolic acidosis |
| Renal | Acute kidney injury (pre-renal) from dehydration |
| Neurological | Febrile seizures (Rotavirus, Shigella); Encephalopathy (Shigella - Ekiri syndrome); Haemolytic Uraemic Syndrome (HUS) from EHEC (E. coli O157:H7) ⭐ |
| GI | Intussusception (post-Rotavirus); Toxic megacolon (Shigella, C. difficile); Intestinal perforation; Rectal prolapse (Shigella in malnourished) |
| Nutritional | Malnutrition and growth faltering (persistent/chronic diarrhoea) |
| Long-term | Post-infectious IBS; Reactive arthritis (Reiter's syndrome - after Shigella, Salmonella, Campylobacter) |
| Treatment complications | Hypernatraemia from incorrect ORS preparation; antibiotic resistance |
⭐ Most dangerous complication: Severe dehydration → Hypovolaemic shock ⭐ Important specific complication: HUS from EHEC (E. coli O157:H7) - microangiopathic haemolytic anaemia + thrombocytopenia + acute kidney injury
| Vaccine | Disease | Type | Schedule (India UIP) |
|---|---|---|---|
| Rotavirus vaccine (RVV) | Rotavirus diarrhoea | Live attenuated oral | 6, 10, 14 weeks (introduced in India UIP 2016) ⭐ |
| Oral Cholera Vaccine (OCV) | Cholera | Killed oral (Shanchol/OrcVax) | 2 doses, 2 weeks apart; used in outbreak settings |
| Typhoid vaccine | Typhoid (enteric fever) | Vi polysaccharide / TCV | UIP: Typhoid Conjugate Vaccine (TCV) from 9-12 months |
| Program | Details |
|---|---|
| National ORT Programme | Promotion of ORS at all levels; ORS packets distributed through ASHA/AWW |
| National Zinc Programme | Zinc co-administered with ORS since WHO 2004 recommendation |
| Swachh Bharat Mission (SBM) | Launched 2 Oct 2014; ODF India declared 2019; critical for diarrhoea prevention ⭐ |
| IMNCI | Community management of childhood diarrhoea by front-line health workers |
| Rotavirus vaccine in UIP | Introduced April 2016; phased rollout across India ⭐ |
| Jal Jeevan Mission | Piped tap water to all rural households by 2024 - major diarrhoea prevention tool |
| WHO target | End preventable child deaths; reduce under-5 mortality (SDG 3.2) |
| Surveillance | IDSP, IHIP, NVBDCP (for cholera), HMIS |
| Always Mention | Key Facts |
|---|---|
| Incubation period | Varies by agent (Staph 1-6 hrs → Giardia 1-3 weeks) |
| Period of communicability | Throughout symptomatic period |
| Notifiable | Cholera - YES (IHR 2005 PHEIC); all outbreaks under IDSP |
| Most common cause in children | Rotavirus (globally); Norovirus (post-vaccination era in US) |
| Drug of choice for Cholera | Doxycycline single dose (adults) |
| Drug of choice for Amoebic dysentery | Metronidazole + Diloxanide furoate |
| Cornerstone of treatment | ORS (Plan A/B/C) + Zinc ⭐ |
| Most dangerous complication | Severe dehydration → shock |
| HUS caused by | EHEC (E. coli O157:H7) ⭐ |
| National program | Swachh Bharat Mission (2014) + ORT Programme + Rotavirus vaccine (UIP 2016) |
| Rice-water stools | Cholera (pathognomonic) |
| Raspberry jelly stools | Amoebic dysentery |
| ORS osmolarity | 245 mOsm/L (low osmolarity WHO formula, 2003) |
| Zinc dose | 20 mg/day x 14 days (10 mg in <6 months) |
Cholera
| Parameter | Details |
|---|---|
| Causative agent | Vibrio cholerae - curved Gram-negative bacillus, Family Vibriaceae |
| Serogroups | O1 and O139 (epidemic potential); non-O1/non-O139 cause sporadic disease only |
| Biotypes of O1 | Classic (caused pandemics 1-6; now extinct) and El Tor (7th pandemic; currently ongoing) ⭐ |
| Serotypes of O1 | Inaba, Ogawa, Hikojima |
| O139 | Emerged 1992 in southeastern India; Bengal serogroup; not cross-protective with O1 |
| Virulence factor | Cholera Toxin (CT) - A+B subunits; B binds GM1 ganglioside → A subunit ADP-ribosylates Gs protein → ↑cAMP → ↑Cl⁻ secretion + ↓Na⁺ absorption → massive fluid loss ⭐ |
| Source of infection | Infected humans (cases + carriers); aquatic environment |
| Reservoir | Aquatic (estuaries, brackish water, plankton/copepods); Human gut |
| Infective material | Faeces (primarily), vomitus |
| Infective dose | 10³-10⁸ via water; 10²-10⁴ via food (gastric acid provides partial protection) |
| Pathogenicity | El Tor: more asymptomatic cases than classic biotype; O blood group at highest risk of severe disease |
| Parameter | Details |
|---|---|
| Age group | Children >2 years in endemic areas; all ages in epidemics/new areas |
| Sex | No significant difference |
| Blood group | Blood group O → highest risk of severe disease ⭐; Blood group AB → least risk |
| Immunity | Natural infection confers immunity for 3 years; type-specific (O1 immunity does NOT protect against O139) |
| Susceptibility increased by | Achlorhydria, H. pylori infection (hypochlorhydria), use of PPIs/antacids, malnutrition |
| Herd immunity threshold | ~60-80% (vaccine-dependent) |
| Parameter | Details |
|---|---|
| Mode | Faecal-oral (primarily waterborne; also foodborne) |
| Vehicle | Contaminated water (#1), contaminated food (shellfish, raw seafood, rice, vegetables), hands |
| Portal of entry | GI tract (oral ingestion) |
| No animal reservoir | Anthroponosis (humans only for transmission; environment is a reservoir) |
| Person-to-person | Less common (large inoculum needed); but household attack rate ~50% in endemic areas |
| Incubation period | Few hours to 5 days (usually 24-48 hours) ⭐ |
| Period of communicability | Throughout symptomatic phase (stool positive); El Tor carriers shed for weeks to months; chronic gallbladder carrier state possible |
| Stage | Features |
|---|---|
| Incubation period | Few hours to 5 days (usually 24-48 hours) |
| Prodromal stage | Usually absent - sudden onset |
| Acute phase (Fastigium) | Sudden painless profuse watery diarrhoea ± vomiting; NO fever; muscle cramps |
| Progression | Rapid dehydration → shock → death if untreated (can die within hours) |
| Convalescence | Full recovery with adequate rehydration; self-limiting in 2-5 days |
| Degree | Clinical Signs | % Body Weight Loss |
|---|---|---|
| None/Mild | Thirst only | <5% |
| Moderate | Thirst, postural hypotension, tachycardia, decreased skin turgor, dry mucosa | 5-10% |
| Severe ⭐ | Unconscious/lethargic, absent pulse, sunken eyes, cannot drink, washerwoman skin | >10% |
| Type | Features |
|---|---|
| Asymptomatic | Majority (El Tor biotype especially); subclinical infection |
| Cholera sicca | Severe form with massive fluid sequestration in gut but minimal external diarrhoea; severe shock; often fatal before diarrhoea appears ⭐ |
| Cholera gravis | Classic severe cholera with profuse rice-water diarrhoea, rapid dehydration, shock |
| Mild cholera | Watery diarrhoea resembling ordinary gastroenteritis; self-limiting |
| Investigation | Details |
|---|---|
| Clinical diagnosis | Patient ≥5 years + acute watery diarrhoea + severe dehydration in endemic/epidemic area |
| Routine labs | Elevated haematocrit (haemoconcentration), elevated BUN/creatinine, ↓bicarbonate (<15 mmol/L), elevated anion gap, low arterial pH (~7.2), normal Na⁺/K⁺/Cl⁻ initially |
| Stool microscopy (Hanging drop) | ⭐ Darting motility ("shooting star" motility) of vibrios; immobilisation by specific O1 antisera confirms diagnosis |
| Dark field microscopy | Curved rods with characteristic motility in fresh stool |
| Stool culture (Gold standard) | ⭐ Selective media: TCBS agar (Thiosulphate Citrate Bile Salt Sucrose) - yellow colonies; or Alkaline Peptone Water (APW) enrichment broth (pH 8.6) |
| Rapid diagnostic test (RDT) | Cholera RDT dipstick - bedside; useful in field/outbreak settings |
| PCR | For O1/O139 confirmation and biotyping |
| Serology | Vibriocidal antibody titres - for epidemiological studies |
| Definition | Criteria |
|---|---|
| Suspected case | Patient ≥5 years with acute watery diarrhoea and severe dehydration OR death from acute watery diarrhoea, in a cholera-affected area |
| Confirmed case | Suspected case + V. cholerae O1 or O139 isolated from stool |
| Notifiable? | ⭐ YES - Cholera is a MANDATORY notifiable disease under IDSP; also under IHR 2005 - potential Public Health Emergency of International Concern (PHEIC); report to CMO within 24 hours |
"The death from cholera is due to hypovolaemic shock; thus treatment first and foremost requires fluid resuscitation." - Harrison's
| Severity | Treatment | Volume |
|---|---|---|
| None/Mild (Plan A) | ORS at home | 50-100 mL after each loose stool |
| Moderate (Plan B) | ORS in facility | Age/weight-based (e.g., ≥15 years: 2200-4000 mL over 4 hrs) |
| Severe (Plan C) ⭐ | IV Ringer's Lactate | 100 mL/kg in first 3 hours (adults); 6 hours (children <12 months); start RAPIDLY then slow |
If Ringer's Lactate unavailable → Normal Saline (0.9% NaCl) Reassess every 15-30 minutes during IV resuscitation
| Parameter | Details |
|---|---|
| Antibiotics | Shorten duration of diarrhoea and reduce fluid loss by ~50%; NOT a substitute for rehydration |
| Drug of choice (adults) | ⭐ Doxycycline 300 mg - single dose (most effective, cheapest) |
| Drug of choice (children) | Azithromycin 20 mg/kg - single dose |
| Drug of choice (pregnant) | Azithromycin 1g - single dose |
| Alternatives | Tetracycline 500 mg QDS x 3 days; Ciprofloxacin 1g single dose; Erythromycin |
| Resistance | Tetracycline/doxycycline resistance reported from Bangladesh, India; check local antibiogram |
| Zinc supplementation | 20 mg/day x 14 days in children (adjunct) |
| Type | Complication |
|---|---|
| Immediate / Acute | ⭐ Hypovolaemic shock → Death (most dangerous; can occur within 4-12 hours of onset) |
| Metabolic | Hypokalaemia (muscle cramps, cardiac arrhythmia), Metabolic acidosis, Hyponatraemia |
| Renal | Acute Kidney Injury / Acute Tubular Necrosis (from profound hypoperfusion) ⭐ |
| Cardiovascular | Cardiac arrhythmias (from hypokalaemia); circulatory collapse |
| Pulmonary | Aspiration pneumonia (from vomiting in obtunded patient) |
| Obstetric | Intrauterine fetal death, premature labour in pregnant women |
| Treatment complications | Fluid overload (cerebral oedema in children if over-rapid rehydration); antibiotic resistance |
| "Cholera sicca" | Paradoxical - death from shock before diarrhoea appears (fluid sequestered in gut) ⭐ |
⭐ Most dangerous complication: Hypovolaemic shock - can kill in hours With adequate rehydration: case fatality rate (CFR) <1%; without treatment: CFR 25-50%
| Vaccine | Type | Efficacy | Schedule |
|---|---|---|---|
| Shanchol (OCV) | Killed oral bivalent (O1 + O139) | ~65-85% for 2 years | 2 doses, 2 weeks apart (≥1 year of age) ⭐ |
| OrcVax (mORCVAX) | Killed oral | Similar | 2 doses |
| Dukoral | Killed oral + recombinant B subunit | ~85% short-term | 2 doses (travellers) |
| Old killed parenteral vaccine | Killed parenteral (injectable) | Only 50%; short duration | No longer recommended ⭐ |
Cholera vaccine is NOT included in India's UIP - used in outbreak/endemic settings and for travellers
| Program | Details |
|---|---|
| National Cholera Control Programme | India - surveillance, case management, OCV stockpile |
| Swachh Bharat Mission | Launched 2 Oct 2014; ODF India - major preventive tool ⭐ |
| Jal Jeevan Mission | Safe piped water to all rural households - key prevention |
| IDSP | All outbreaks and cases reported; War room surveillance |
| WHO Global Task Force on Cholera Control (GTFCC) | "Ending Cholera: A Global Roadmap to 2030" - target 90% reduction in cholera deaths by 2030 ⭐ |
| Global OCV Stockpile | WHO/UNICEF/MSF maintain emergency oral cholera vaccine stockpile for outbreak response |
| IHR 2005 | Cholera - potential PHEIC; international notification mandatory |
| Always Mention | Key Facts |
|---|---|
| Incubation period | Few hours to 5 days (usually 24-48 hrs) |
| Period of communicability | Throughout symptomatic phase; El Tor - weeks in carriers |
| Notifiable | YES - IHR 2005 + IDSP mandatory |
| Causative agent | V. cholerae O1 (El Tor biotype) / O139 |
| 7th Pandemic began | 1961, Indonesia (El Tor biotype) ⭐ |
| Pathognomonic sign | Rice-water stools + washerwoman skin ⭐ |
| Drug of choice | Doxycycline 300 mg single dose (adults) ⭐ |
| Cornerstone of treatment | Rehydration (ORS Plan A/B; Ringer's Lactate Plan C) ⭐ |
| Gold standard diagnosis | Stool culture on TCBS agar ⭐ |
| Hanging drop test | Darting motility of vibrios |
| Most dangerous complication | Hypovolaemic shock (CFR 25-50% untreated; <1% treated) |
| Blood group risk | Blood group O = highest risk ⭐ |
| Cholera toxin mechanism | ↑cAMP → ↑Cl⁻ secretion → rice-water stool ⭐ |
| WHO 2030 goal | 90% reduction in cholera deaths |
Cjolera
| Section | Key Points |
|---|---|
| Agent | Vibrio cholerae O1 (El Tor biotype) / O139; curved Gram-negative bacillus |
| Reservoir | Aquatic environment + human gut; NO animal reservoir |
| Transmission | Faecal-oral; contaminated water (#1); incubation 24-48 hrs |
| Pathognomonic | ⭐ Rice-water stools + washerwoman skin; NO fever, NO blood |
| Virulence | Cholera toxin → ↑cAMP → massive Cl⁻/water secretion |
| Diagnosis (Gold std) | Stool culture on TCBS agar; hanging drop = darting motility |
| Treatment | ⭐ Rehydration FIRST (ORS/Ringer's Lactate) + Doxycycline 300 mg single dose |
| Most dangerous | Hypovolaemic shock (CFR 25-50% untreated; <1% with treatment) |
| Vaccine | Shanchol (killed oral, 2 doses) - NOT in UIP |
| 7th Pandemic | 1961, Indonesia (El Tor biotype); currently ongoing |
| WHO 2030 goal | 90% reduction in cholera deaths |
Typhoid
| Parameter | Details |
|---|---|
| Causative agent | Salmonella typhi (primary); S. paratyphi A, B, C (paratyphoid - milder disease) |
| Type | Gram-negative bacillus, Family Enterobacteriaceae; facultative intracellular pathogen |
| Antigens | O antigen (somatic - rises in disease), H antigen (flagellar - rises with vaccination), Vi antigen (virulence capsular antigen - present in 80% of chronic carriers) ⭐ |
| Phage types | At least 80 phage types - used for epidemiological tracing of outbreaks |
| Source of infection | Faeces and urine of cases/carriers (primary); contaminated water, food, fingers, flies (secondary) |
| Reservoir | Human only - strict anthroponosis (NO animal reservoir) ⭐ |
| Infective material | Faeces (primary), urine |
| Survival | Survives in water 7 days; ice and ice cream >1 month; soil irrigated with sewage up to 70 days; multiplies rapidly in milk |
| Carrier state | Temporary (incubatory, convalescent) and Chronic (excrete >1 year, usually in gall bladder); 2-5% of cases become chronic carriers; "Typhoid Mary" - famous example ⭐ |
| MDR strains | Resistance to chloramphenicol + ampicillin + cotrimoxazole = MDR S. typhi; XDR (extensively drug resistant) strains also reported from Pakistan |
| Parameter | Details |
|---|---|
| Age group | Any age; highest incidence in 5-19 years; school-age and young adults ⭐ |
| Sex | More cases in males (greater exposure); but carrier rate higher in females ⭐ |
| Immunity | Cell-mediated immunity (CMI) is primary defence (intracellular organism); antibodies are secondary; natural infection does NOT always confer solid immunity |
| Susceptibility increased by | Achlorhydria, H. pylori infection, PPIs, malnutrition, immunocompromise |
| Chronic carrier risk | Higher in women, infants, those with biliary abnormalities or Schistosoma haematobium bladder infection |
| Parameter | Details |
|---|---|
| Mode | Faecal-oral (primary) and urine-oral |
| Routes (5 Fs) | Fluids (contaminated water/ice), Food (especially milk, shellfish, vegetables), Fingers (hand contamination), Flies, Fomites |
| No respiratory transmission | S. typhi NOT excreted in sputum; NOT spread by droplet |
| Portal of entry | GI tract (oral ingestion) |
| Incubation period | Usually 10-14 days (range 3-21 days depending on inoculum size) ⭐ |
| Period of communicability | Throughout clinical illness and carrier state; convalescent carriers shed for 6-8 weeks; chronic carriers shed for years (intermittently or continuously) |
| Week | Stage | Features |
|---|---|---|
| Week 1 | Prodromal / Incubation | Gradual onset fever (step-ladder pattern), headache, malaise, anorexia, dry cough, coated tongue, constipation (children may have diarrhoea) |
| Week 2 | Fastigium (Stage of invasion) | Continuous high fever (39-40°C), relative bradycardia, Rose spots appear, splenomegaly, hepatomegaly, toxic appearance |
| Week 3 | Stage of maximum illness | Fever sustained; complications appear (perforation, bleeding); "muttering delirium / coma vigil"; patient picks at bedclothes |
| Week 4 | Defervescence / Convalescence | Gradual resolution; fever decreases; recovery begins; relapse possible |
| Type | Features |
|---|---|
| Typical typhoid | Classic 4-week illness with all features above |
| Mild/ambulatory typhoid | Subclinical or mild febrile illness; common in endemic areas with partial immunity |
| Typhoid of infancy | Vomiting, diarrhoea, convulsions; high mortality |
| Complicated typhoid | With intestinal perforation, haemorrhage, or neurological involvement |
| Paratyphoid | Caused by S. paratyphi A/B/C; shorter, milder course; similar clinical picture |
| Carrier state | Chronic asymptomatic carrier - most in gall bladder; 2-5% of cases |
| Investigation | Details | Timing |
|---|---|---|
| Blood culture | 40-60% sensitivity; best in Week 1 (bacteraemia peaks) | Week 1-2 ⭐ |
| Bone marrow culture | ⭐ GOLD STANDARD - ~80% sensitivity; not reduced by prior antibiotics (up to 5 days) | Any time |
| Stool culture | Positive in Week 3-4 (when organism shed in bile back into gut) | Week 3-4 |
| Urine culture | Positive in Week 3-4 | Week 3-4 |
| String (duodenal) test | Captures intestinal secretions; useful for carriers; combined with above gives >90% yield | Any time |
| Widal test | Agglutination test - O titre ≥1:160 (active disease); H titre ≥1:160 (past infection/vaccination); NOT reliable as standalone - many false positives/negatives ⭐ | Week 2 onwards |
| Typhidot / TUBEX | Rapid IgM/IgG detection; sensitivity ~70-80%, specificity ~80-90%; useful point-of-care | Week 1-2 |
| CBC | Leucopenia + neutropenia (15-25% of cases) ⭐; raised ESR; mild anaemia; thrombocytopenia in severe disease | |
| LFT | Moderately raised transaminases; mild jaundice in hepatitis form |
| Titre | Interpretation |
|---|---|
| O antigen ≥1:160 | Active infection (O titre is diagnostic) |
| H antigen ≥1:160 | Past infection OR vaccination (H titre persists) |
| Rising titre (4-fold) | Confirms active infection |
| Vi antigen positive | Carrier state (80% of chronic carriers) |
| Definition | Criteria |
|---|---|
| Suspected case | Fever ≥38°C for ≥3 days + compatible clinical features (headache, abdominal pain, rose spots) |
| Probable case | Suspected case + positive Widal/Typhidot test |
| Confirmed case | ⭐ S. typhi or S. paratyphi isolated from blood/bone marrow/stool/urine culture |
| Notifiable? | YES - notifiable under IDSP; report to CMO |
| Indication | Drug | Dose | Duration |
|---|---|---|---|
| Empirical (unknown susceptibility) | Ceftriaxone (IV) OR Azithromycin (oral) | Ceftriaxone 2g/day IV; Azithromycin 1g day 1 then 500 mg OD | 7-14 days |
| Fully sensitive S. typhi | Chloramphenicol OR Ampicillin OR Cotrimoxazole | Chloramphenicol 25 mg/kg/day | 14 days |
| MDR S. typhi (resistant to Chlor/Amp/Cotrim) | Ceftriaxone OR Azithromycin | As above | 7-10 days |
| XDR S. typhi (also resistant to FQ + 3rd gen cephalosporins) | Azithromycin | 1g then 500 mg OD | 7 days |
| Decreased susceptibility to Ciprofloxacin (DSC) | Avoid fluoroquinolones; use Azithromycin or Ceftriaxone | ||
| Uncomplicated (where FQ still sensitive) | Ciprofloxacin 500 mg BD | 7-10 days |
⭐ Note for India/PSM exams: Traditional teaching = Chloramphenicol was the original DOC; now Ceftriaxone or Azithromycin are preferred due to widespread MDR. Fluoroquinolones NO LONGER first-line on Indian subcontinent due to DSC strains.
| Type | Complication |
|---|---|
| GI - Most common ⭐ | Intestinal perforation (1%) - Week 3-4; ileal Peyer's patches ulcerate; acute abdomen; requires emergency surgery + broad-spectrum antibiotics ⭐ |
| GI - Second most common | Intestinal haemorrhage (6%) - Week 3-4; melaena or fresh blood PR; transfusion may be needed |
| Hepatic | Typhoid hepatitis, hepatomegaly, jaundice |
| Splenic | Splenic rupture (rare but dramatic) |
| Neurological (2-40%) | Typhoid encephalopathy / Muttering delirium / Coma vigil ⭐; meningitis; Guillain-Barré syndrome; neuritis |
| Cardiovascular | Myocarditis; circulatory collapse; DIC |
| Haematological | Thrombocytopenia; DIC; haemolytic anaemia |
| Respiratory | Pneumonia; rarely pleuritis |
| Renal | Glomerulonephritis; HUS (rare) |
| Relapse | Up to 10% of cases; occurs 2-3 weeks after fever resolution; same strain ⭐ |
| Carrier state | 2-5% become chronic carriers (gall bladder); associated with increased risk of gallbladder cancer ⭐ |
| Complications of treatment | Herxheimer-like reaction; antibiotic resistance |
⭐ Most dangerous acute complication: Intestinal perforation (mortality 10-32%) CFR: 2.5% overall; 10-30% if untreated; <1% with prompt treatment
| Vaccine | Type | Efficacy | Route | Schedule | Duration |
|---|---|---|---|---|---|
| TAB vaccine (old, killed parenteral) | Killed whole-cell | ~70-90% short-term | SC injection | 2 doses 4 weeks apart + booster every 3 years | 3 years; NOW largely REPLACED |
| Vi polysaccharide vaccine (Typherix/Typhim Vi) | Purified Vi capsular polysaccharide | ~60-80% | IM/SC; single dose | Single dose; booster every 3 years | 3 years; for adults + children >2 yrs |
| ⭐ Typhoid Conjugate Vaccine (TCV - Typbar-TCV) | Vi polysaccharide conjugated to tetanus toxoid | ~80-85% | IM; single dose | India UIP: Single dose at 9-12 months (introduced 2021-22) ⭐ | Long-lasting; T-cell dependent immunity |
| Ty21a (Vivotif) | Live attenuated oral | ~67-80% | Oral; 3-4 capsules alternate days | Not in India UIP; used in travellers | 5 years |
⭐ Key exam fact: TCV (Typhoid Conjugate Vaccine) introduced into India's UIP as a single dose at 9-12 months - conjugation allows use in infants <2 years (Vi polysaccharide alone is T-independent - ineffective <2 yrs)
| Program | Details |
|---|---|
| Typhoid Conjugate Vaccine in UIP | Single dose at 9-12 months; India phased rollout 2021-22 ⭐ |
| Swachh Bharat Mission | ODF India; launched 2 Oct 2014; most effective typhoid prevention at population level ⭐ |
| Jal Jeevan Mission | Safe piped water to all rural households |
| IDSP | Surveillance; typhoid is notifiable |
| WHO target | Promote TCV globally; integrate into childhood immunization schedules in endemic countries |
| Always Mention | Key Facts |
|---|---|
| Incubation period | 10-14 days (range 3-21 days) ⭐ |
| Period of communicability | Throughout illness + carrier state |
| Notifiable | YES - under IDSP |
| Reservoir | Human only (no animal reservoir) ⭐ |
| Hallmark clinical features | Step-ladder fever + relative bradycardia + rose spots ⭐ |
| Week of complications | Week 3-4 (perforation, bleeding) ⭐ |
| Gold standard diagnosis | Bone marrow culture (~80% sensitivity) ⭐ |
| Best practical diagnosis | Blood culture in Week 1 |
| Widal interpretation | O titre ≥1:160 = active disease; Vi = carrier |
| Most dangerous complication | Intestinal perforation ⭐ |
| Drug of choice | Ceftriaxone or Azithromycin (MDR era) ⭐ |
| Isolation duration | Until 3 negative stool + urine cultures ⭐ |
| Carrier female example | "Typhoid Mary" ⭐ |
| Vaccine in India UIP | TCV (Typhoid Conjugate Vaccine) - 9-12 months ⭐ |
| National program | Swachh Bharat Mission + TCV in UIP |
| Carrier percentage | 2-5% of cases become chronic carriers |
| Carrier Vi antigen | Positive in 80% of chronic carriers |
Food poisoning
Note for exam: Food poisoning is a syndrome caused by multiple agents. In PSM exams, questions usually ask you to compare types in a table or describe the most important types (Staphylococcal, Salmonella, Botulism, Cl. perfringens, B. cereus). Always define it first, then cover each type systematically.
| Type | Agent | Mechanism |
|---|---|---|
| Toxic (Intoxication) | Staph. aureus, Cl. botulinum, B. cereus (emetic) | Preformed toxin in food ingested (intradietetic toxin) - NO bacterial multiplication in gut needed |
| Infective | Salmonella spp., ETEC, Vibrio | Living bacteria ingested → multiply in gut → toxin produced in vivo |
| Mixed | Cl. perfringens, B. cereus (diarrhoeal) | Bacteria ingested → sporulate/multiply → produce toxin in gut |
| Feature | Salmonella | Staph. aureus | Cl. botulinum | Cl. perfringens | B. cereus |
|---|---|---|---|---|---|
| Type | Infective | Toxic (preformed) | Toxic (preformed) | Mixed | Mixed (2 types) |
| Agent | S. typhimurium, S. enteritidis | Coagulase +ve Staph. aureus (enterotoxin) | Exotoxin types A, B, E | Alpha toxin | Emetic toxin / Diarrhoeal enterotoxin |
| Incubation | 12-24 hrs | 1-8 hrs (shortest!) | 18-36 hrs | 6-24 hrs (peak 10-14 hrs) | Emetic: 1-5 hrs; Diarrhoeal: 8-16 hrs |
| Common food | Meat, eggs, poultry, milk | Custards, salads, milk, pastries, ham | Home-canned veg, smoked fish, home-made cheese | Meat dishes, poultry (cooked and reheated) | Fried/boiled rice (emetic); meat/vegetables (diarrhoeal) |
| Fever | YES (chills, fever) | NO ⭐ | NO | NO/minimal | NO |
| Vomiting | YES | YES (prominent) | Minimal | Rare | YES (emetic type) |
| Diarrhoea | YES (watery) | YES | NO/minimal | YES | YES (diarrhoeal type) |
| Key feature | Fever + gastroenteritis | Vomiting prominent, NO fever, short IP | Neurological symptoms ⭐ | Diarrhoea + cramps, NO vomiting | "Fried rice illness" (emetic type) |
| Duration | 2-3 days | <24 hrs | 4-8 days (fatal) | <24 hrs (1 day) | <24 hrs |
| Parameter | Details |
|---|---|
| Age group | All ages; elderly, infants, immunocompromised at highest risk of severity |
| Sex | No significant difference |
| Risk factors | Improper food storage, mass/community feeding, banquets/weddings, food handler as carrier, immunocompromise |
| Susceptibility | Universal; gastric acidity is a partial protective barrier |
| Parameter | Details |
|---|---|
| Mode | Ingestion of contaminated food (NOT person-to-person in most types) |
| Vehicle | Specific foods for each type (see table above) |
| Key characteristic | Explosive point-source outbreak - many people affected simultaneously after a common meal ⭐ |
| Portal of entry | GI tract |
| Incubation period | Varies by agent (1-8 hrs = Staph; 18-36 hrs = Botulism; 12-24 hrs = Salmonella) |
| NOT communicable | Food poisoning is NOT communicable person-to-person (except Salmonella which can spread secondarily) |
| Stage | Features |
|---|---|
| Incubation period | Very short (1-8 hrs for toxin types) to 12-36 hrs for infective types |
| Prodromal | Usually absent - sudden onset |
| Acute phase | Nausea, vomiting, diarrhoea, abdominal cramps - vary by agent |
| Convalescence | Rapid recovery in most types (except botulism); usually self-limiting |
| Grade | Features |
|---|---|
| Mild | Self-limiting GI symptoms; no dehydration |
| Moderate | Significant vomiting/diarrhoea; some dehydration |
| Severe | Severe dehydration, electrolyte imbalance, shock (Salmonella); respiratory paralysis (Botulism) |
| Investigation | Details |
|---|---|
| Clinical diagnosis | Explosive outbreak + common food + similar symptoms + short incubation period |
| Stool examination | Microscopy (pus cells, RBCs); culture (Salmonella) |
| Food culture | Culture of implicated food - most important in outbreak investigation ⭐ |
| Vomitus culture | Staph. aureus (coagulase-positive) |
| Food toxin testing | ELISA for staphylococcal enterotoxin; mouse bioassay for botulinum toxin ⭐ |
| Blood culture | In Salmonella bacteraemia |
| Stool for Cl. perfringens | >10⁵ organisms/g in implicated food |
| Serum botulinum toxin | Mouse inoculation test - gold standard for botulism |
| CBC | Leucocytosis in infective type (Salmonella); normal in toxic type (Staph) |
| Electrolytes | For dehydration assessment |
| Definition | Criteria |
|---|---|
| Suspected outbreak | ≥2 persons with similar illness after consuming a common food |
| Confirmed case | Isolation of pathogen from food/stool/blood OR detection of toxin |
| Botulism suspected | Descending paralysis after eating home-preserved food |
| Notifiable? | YES - all food poisoning outbreaks are notifiable under IDSP; report to CMO and Food Safety Officer (FSSAI) within 24 hours ⭐ |
| Agent | Specific Treatment | Notes |
|---|---|---|
| Salmonella | Usually supportive; Ciprofloxacin or Azithromycin if severe/bacteraemic | Antibiotics NOT needed for mild cases (may prolong carrier state) |
| Staph. aureus | Supportive only - antibiotics NOT indicated ⭐ | Preformed toxin - antibiotics useless; rapid recovery |
| Botulism ⭐ | Trivalent botulinum antitoxin (A, B, E) 50,000-100,000 units IV + respiratory support (ICU/ventilator) | Antitoxin only works BEFORE toxin binds to nerve; respiratory support may be needed for weeks |
| Cl. perfringens | Supportive only | Self-limiting; no antibiotics needed |
| B. cereus | Supportive only | Self-limiting; no antibiotics needed |
⭐ Key exam point: Antibiotics are generally NOT indicated in food poisoning (toxic types). Exception: severe Salmonella with bacteraemia or risk of systemic spread.
| Type | Complication |
|---|---|
| Immediate / Acute | ⭐ Respiratory failure in Botulism (MOST DANGEROUS) - requires ventilator |
| Fluid/Electrolyte | Severe dehydration, hypovolaemic shock, hyponatraemia, hypokalaemia (especially Salmonella) |
| Renal | Acute kidney injury from dehydration |
| Neurological | Descending paralysis, cranial nerve palsies, diplopia (Botulism) ⭐ |
| GI | Intestinal perforation/bleeding (rare, in Salmonella); toxic megacolon (rare) |
| Haematological | HUS (Haemolytic Uraemic Syndrome) from EHEC (E. coli O157:H7) ⭐ |
| Long-term | Post-infectious IBS; Reactive arthritis (after Salmonella); chronic carrier state (Salmonella) |
| Mortality | Botulism: 2/3 die if untreated ⭐; Salmonella: ~1% CFR |
⭐ Most dangerous form: Botulism - respiratory failure; kills 2/3 untreated ⭐ Most common form: Staphylococcal food poisoning (equally common as Salmonella)
| Measure | Details |
|---|---|
| Botulinum toxoid | Available for laboratory workers and high-risk groups; NOT in general use |
| Cold chain maintenance | Refrigeration of perishable foods; cold chain for dairy/meat products |
| Food irradiation | WHO-approved method to kill pathogens in food |
| Pasteurisation | Kills Salmonella, Staph in milk and dairy products |
| HACCP | Hazard Analysis Critical Control Points - food industry standard ⭐ |
| Food handler screening | Stool cultures of food handlers in high-risk settings; nasal swabs for Staph carriage |
| Antitoxin prophylaxis | Botulinum antitoxin given to all persons who ate the implicated food in a botulism outbreak ⭐ |
| Program | Details |
|---|---|
| FSSAI (Food Safety and Standards Authority of India) | Established under Food Safety and Standards Act, 2006 ⭐; regulates food safety, licensing, standards; key body for food poisoning prevention |
| IDSP | All food poisoning outbreaks notifiable; P-form + L-form surveillance |
| SWACHH BHARAT MISSION | Improved sanitation reduces food contamination |
| WHO "Five Keys to Safer Food" ⭐ | 1. Keep clean; 2. Separate raw and cooked; 3. Cook thoroughly; 4. Keep food at safe temperatures; 5. Use safe water and raw materials |
| WHO Global Foodborne Disease Burden | 600 million cases/year; 420,000 deaths; SDG 2 (Zero Hunger) and SDG 3 (Good Health) relevant |
| Always Mention | Key Facts |
|---|---|
| Shortest incubation | Staph. aureus: 1-8 hours ⭐ |
| Longest incubation | Botulism: 18-36 hours |
| Most serious | Botulism (kills 2/3 untreated) ⭐ |
| Most common | Staph. aureus and Salmonella (equally common) |
| NO fever | Staph. aureus, Botulism, Cl. perfringens ⭐ |
| NO vomiting | Cl. perfringens ("diarrhoea only") ⭐ |
| Neurological symptoms | Botulism only ⭐ |
| "Fried rice illness" | B. cereus (emetic type) ⭐ |
| Treatment for Botulism | Trivalent antitoxin + ventilator ⭐ |
| Antibiotics NOT indicated | Staph, Cl. perfringens, B. cereus, mild Salmonella ⭐ |
| Gold standard for botulism | Mouse bioassay for toxin |
| Notifiable | YES - all outbreaks to CMO + FSSAI |
| Key regulatory body | FSSAI (Food Safety and Standards Act, 2006) |
| WHO Five Keys | Keep clean; Separate raw/cooked; Cook thoroughly; Safe temperatures; Safe water |
| Epidemic curve pattern | Explosive point-source; narrow single peak ⭐ |